Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parecoxib plus imrecoxib for prevention of severe acute pancreatitis
ChiCTR2000032434Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of parecoxib and imrecoxib in acute pancreatitis (AP) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of severe acute pancreatitis and Organ failure scores. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
parecoxibimrecoxib
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on ChiCTR2000032434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032434.